InflaRx N.V. Share Price & Technical Analysis
IFRX · $2.73 (+4.60%)
Healthcare / Biotechnology
$2.73
+4.60%
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinica…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
30% return in May, -22% avg return in past 3 year May month.
153% return in 2026, 19% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -10% | 0% | 0% | 133% | 30% | – | – | – | – | – | – | – | 153% |
| 25 | -4% | -39% | -29% | 70% | -53% | 0% | 13% | 78% | -24% | 7% | -7% | -17% | -5% |
| 24 | 0% | 13% | -17% | -7% | 0% | 13% | -17% | 0% | -6% | 0% | 67% | 0% | 46% |
| 23 | -29% | -14% | 0% | 145% | -14% | 7% | -5% | -2% | -25% | -43% | -18% | 14% | 17% |
| 22 | -25% | -25% | -31% | -15% | -6% | -6% | 80% | -24% | 18% | 0% | 0% | 19% | -15% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$170.61M
P/E ratio
—
52W high
$2.95
52W low
$0.71
Volume
3,45,383
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is InflaRx N.V. share price today?
- InflaRx N.V. (IFRX) last traded around $2.73 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IFRX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IFRX. Download the app for real-time alerts.
- How can I analyze InflaRx N.V. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.